Two-year data presented at ESCRS 2026 show the ELIOS excimer laser procedure sustained IOP reduction and kept most glaucoma patients medication-free.
News
Advertisement
At ESCRS 2026, Zoltan Z. Nagy, MD, reported that femtosecond laser trabeculotomy (FLigHT) cut intraocular pressure by 27% at 48 months in open-angle glaucoma, with a stable, incision-free safety profile.
Advertisement
A prospective French study found intraoperative OCT most valuable for measuring key surgical distances in deep sclerectomy and MIGS procedures, and useful for training residents.
ESCRS 2026 real-world data: aceclidine (VIZZ; LENZ Therapeutics) drops show fast onset, high satisfaction for presbyopia.
Three-year ESCRS 2026 data show trans-epithelial PRK matches conventional PRK in refractive outcomes, safety, and pain, with faster surgical time.
ESCRS 2026: enhanced monofocal IOL delivers distance and functional intermediate vision, study finds
A real-world study of an enhanced monofocal IOL found most patients achieved 20/20 distance vision and functional intermediate vision without glasses, according to Jai Parekh, MD, MA, FAAO, at ESCRS 2026.
Advertisement
New ESCRS 2026 data show corneal measurements shift meaningfully across the day, with early-morning readings potentially biased by overnight eyelid closure.
At ESCRS 2026 in London, Radhika Rampat, MBBS, FRCOphth, describes bringing low-level light therapy into her refractive practice, from dry eye care to chalazion treatment and pre-surgical ocular surface optimisation.
In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Aaberg about the science, clinical data, and real-world reception of the first FDA-approved treatment for MacTel type 2.
Suzana Konjevoda, MD, presents data at ESCRS 2026 showing citicoline eye drops aid corneal nerve recovery post-cataract surgery.
Advertisement
ESCRS 2026 study shows multifocal IOLs tie at distance, but reading speed plunges in dim light; focus curves predict laser touch-ups.
Mingo-Botín, MD, PhD, discusses ESCRS 2026 data on an EDOF IOL in post-LASIK eyes vs non-LASIK controls.
Real-world data show tear film and Schirmer improvements with two preservative-free dry eye drops at ESCRS 2026.
The 44th Congress of the ESCRS kicked off at ExCeL London with iNovation Day and the Opening Ceremony, setting the stage for a five-day programme.
Suzana Konjevoda, MD, previews ESCRS 2026, highlighting new IOLs, presbyopia correction, AI in everyday practice, and advances in post-cataract surgery recovery and comfort.
Handheld IC1000 pairs rebound tonometry with camera-guided alignment
The FDA accepted Nanoscope's BLA for MOGENRY (sonpiretigene isteparvovec, MC-010), a gene therapy for retinitis pigmentosa with severe vision loss, supported by RESTORE trial data showing sustained BCVA improvement.
Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye programme.
Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.
Dante Pieramici, MD, discusses the phase 3 COMO and CAPRI trials of EYP-1901 in diabetic macular edema and what 6-month dosing could mean for treatment burden.
Scaling telemedicine-based screening for retinopathy of prematurity in sub-Saharan Africa
ByArthur R. Brant, MD,Sarthak V. Shah, MD,Akwasi Ahmed, MD, MBA,Imoro Braimah, MD,Naana Wireko Brobby, MD,Kwabena Onwona-Agyeman, MD,Dominic Masonuo Bagbio, MD,Gilbert Bonsaana, MD,Samuel Bondzie, MD,Jacquelyn Adu, MD,Muniratu Alhassan, BS,Sadik T. Sherief, MD,Asrat Demptse, MD,Eyerusalem Haregewoyn, MD,Celina Mhina, MD,Martha Mkony, MD,Ahmad Al-Moujahed, MD, PhD,Ahmad Kunbaz, MD,Celine Chaaya, MD, MSc,Cindy S. Zhao, MD, MBA,Geoffrey C. Tabin, MD,Nimesh A. Patel, MD,Darius M. Moshfeghi, MD
Zero Blind Babies uses wide-field retinal imaging and telemedicine to expand ROP screening across Ghana, Ethiopia, Tanzania, and Syria—screening 400 infants weekly at $56 per QALY—while stressing that local staff and complete-pathway systems remain essential.
Dante Pieramici, MD, on how a sustained-release TKI dosed every six months could cut clinic volume, ease treatment burden, and protect patients who otherwise disappear from care.
Jay Chhablani, MD, on how MacTel eyes turn neovascular, when to refer, and what Encelto means for treatment.
Jordi Mones, MD, PhD, discusses what is believed to be the first direct-to-phase 2 trial testing an optogenetic gene therapy to restore vision lost to GA.
Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.
A priority review in Stargardt disease, two pivotal-trial milestones, an emerging bispecific for wet AMD, and new diagnostic guidance defined a busy August for retina.
Researchers from China and Singapore found that the macular microvasculature is altered as early as the pre-diabetic stage of the disease. The findings suggest that the status of the choriocapillaris can be used to monitor early metabolic disease.
Jonathan Gloth, MD, discusses how a dual Tie2/VEGF mechanism could reduce injection burden and the consequences of missed doses in wet AMD.
John W. Kitchens, MD, discusses patient selection for geographic atrophy treatment, counseling approaches, and emerging therapies including a C1q inhibitor and cell-based options.
Reem Amine, MD, discusses why clinic distance predicts loss to follow-up in geographic atrophy and shares one retention check practices can implement now.
Advertisement
Advertisement